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Abstract Mitoxantrone (MTX) is a chemotherapeutic
agent that emerged as an alternative to anthracycline ther-
apy. However, MTX also causes late cardiotoxicity, being
oxidative stress and mitochondrial-impaired function pro-
posed as possible mechanisms. This work aimed to inves-
tigate the relevance of these mechanisms to the MTX
toxicity in H9c2 cells, using therapeutic concentrations. The
observed cytotoxicity of MTX was time and concentration
dependent in both lactate dehydrogenase leakage assay and
MTT reduction assay. Two therapeutic concentrations (100
nM and 1 lM) and three time points were selected (24, 48,
and 96 h) for further studies. Both MTX concentrations
caused a significant increase in caspase-3 activity, which
was not prevented by inhibiting MTX CYP450-metabolism.
Significant decreases were observed in the total and reduced
glutathione levels only in MTX 100 nM at 96 h; however,
neither alterations in oxidized glutathione nor increases in
the malondialdehyde levels were observed at any time or
concentrations tested. On the other hand, changes in the
intracellular ATP levels, mitochondrial membrane poten-
tial, and intracellular calcium levels were observed in both
concentrations and all time tested. Noteworthy, decreased
levels of ATP-synthase expression and activity and
increases in the reactive species generation were observed
at 96 h in both working concentrations. However, the rad-
ical scavenger N-acetylcysteine or the mitochondrial func-
tion enhancer L-carnitine did not prevent MTX cytotoxicity.
Thus, this work evidenced the early MTX-induced ener-
getic crisis as a possible key factor in the cell injury.
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Introduction
Mitoxantrone (MTX) is an anthracenedione chemothera-
peutic agent used in the treatment of solid tumors, such as
breast and prostate cancer, and hematological malignances,
namely acute leukemia and lymphoma [1]. Due to its
immunosuppressive properties, MTX has been also
employed in the treatment of multiple sclerosis [2]. MTX
acts as an intercalating agent being a powerful inhibitor of
DNA and RNA synthesis, and affects the cell cycle at
various stages [3]. Moreover, MTX is an inhibitor of
topoisomerase II [1], and, recently, the MTX potential
epigenetic effects were demonstrated given its high affinity
to bind to histone H1 and core histones in vitro [4].
Due to their similar chemical structure and anticancer
mechanisms, MTX was considered an alternative to
anthracycline chemotherapy with the advantage of allow-
ing the administration of lower relative doses than doxo-
rubicin [5]. However, it became evident after its clinical
use that MTX also promoted late irreversible cardiotoxicity
in up to 18 % of treated patients, which sometimes is
clinically diagnosed several years after treatment [1].
Furthermore, this risk is increased with higher cumulative
doses [1]. MTX is extensively distributed and accumulates
in heart tissue. In fact, MTX is still detected in the human
heart (716 ng/g wet weight) 35 days after a single dose
(12 mg/m2) [6], showing that cardiac cells maintain a
prolonged contact after MTX administration.
The observed heart failure promoted by MTX is clini-
cally similar to that caused by doxorubicin [1]; however,
mechanistic studies of MTX-induced cardiotoxicity are
scarce on the available literature. The cardiac side effects
promoted by doxorubicin have been extensively related to
oxidative stress [7] and to mitochondrial-impaired function
[8]. Studies demonstrated that the oxidoreductive metabo-
lism of MTX produces reactive intermediates [9, 10] and
that MTX shows particular effectiveness against tumors
expressing high content of heme-peroxidases [11], sug-
gesting the involvement of reactive species in its successful
antitumor action. Additionally, its cytotoxicity has already
been prevented by the inhibition of CYP450-mediated
metabolism in human hepatoma-derived cell line [10, 12],
in isolated adult rat hepatocytes [12], and in MCF-7 human
breast cancer cells [13]. In fact, recently, our research
group highlighted that the bioactivation of MTX may also
be involved in its undesirable cardiac side effects since the
cytotoxicity of MTX was partially prevented in a cardio-
myoblast H9c2 cell model by inhibiting CYP450- and
CYP2E1-mediated metabolism [14].
Energetic imbalance was suggested to be a consequence
of MTX treatment. In cultured neonatal rat heart cells, the
3 h incubation with MTX (about 0.1–10 lM) caused a
concentration-dependent decline in the ATP levels after 72 h
[15]. Mitochondrial swelling was observed after electron and
light microscopy in hearts excised from female BALB/c
mice killed 1 week after treatment with MTX (0.2 mg/kg),
intraperitoneal (i.p.), weekly, for 12-week [5]. Furthermore,
cardiac mitochondria isolated from rats treated with MTX
(1 mg/kg i.p.), twice a week, for 4 weeks, showed a reduc-
tion in the electron transfer and the respiratory chain activity
and uncoupling of oxidative phosphorylation [16]. In spite of
these 3 studies, the mitochondrial role on MTX-induced
cardiotoxicity and the mechanisms involved are still poorly
understood due to the lack of focused studies on their func-
tionality while facing MTX.
This work aimed to evaluate the mechanisms involved
in the MTX cardiotoxicity using the H9c2 cells as cellular
model exposed to therapeutic concentrations of this drug.
H9c2 is a cell line derived from rat heart, that is considered
a valuable model to assess in vitro cardiotoxicity [17],
specially due to its metabolic features, which are compa-
rable to those found in rat heart [18]. The work used this
in vitro model to evaluate several mitochondrial and
mitochondrial-related pathways, namely ATP levels,
mitochondrial membrane potential, or ATP-synthase
activity or expression. Other cellular components, which
could be related to mitochondrial functionality, namely
calcium levels, formazan metabolization, reactive species
generation, or glutathione levels were also evaluated. The
use of a CYP450 inhibitor (metyrapone), a CYP2E1
inhibitor (diallyl sulfide), a reactive species scavenger (N-
acetylcysteine [NAC]), and a mitochondrial function
enhancer (L-carnitine) was also performed to evaluate the
role of the respective pathways in MTX cytotoxicity.
Methods
Chemicals
All chemicals and reagents were of analytical grade or of the
highest grade available. MTX hydrochloride, NAC, L-car-
nitine, reduced glutathione (GSH), oxidized glutathione
(GSSG), glutathione reductase (GR, EC 1.6.4.2), 2-vinyl-
pyridine, reduced b-nicotinamide adenine dinucleotide (b-
NADH), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide (MTT), 5,5-dithio-bis(2-nitrobenzoic) acid
(DTNB), the caspase-3 substrate (N-Acetyl-Asp-Glu-Val-
Asp p-nitroanilide), dihydrorhodamine 123 (DHR), lucif-
erin, luciferase, thiobarbituric acid (TBA), protease inhibi-
tors cocktail, anti-goat actin monoclonal antibody, and anti-
rabbit ATP-synthase polyclonal antibody were obtained
from Sigma-Aldrich (St. Louis, MO). Dichlorodihydro-
fluorescein diacetate (DCFH-DA), tetramethylrhodamine
(TMRM), and Fluo-3 AM were obtained from Molecular
Probes (Eugene, OR). Dimethyl sulfoxide (DMSO) and
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perchloric acid (HClO4) were obtained from Merck
(Darmstadt, Germany). The nitrocellulose membranes (Hy-
bond ECL), ECL chemiluminescence detection reagents, the
anti-rabbit and anti-goat IgG peroxidase secondary antibody
were obtained from GE Healthcare (Buckinghamshine, UK).
Flow cytometry reagents (BD Facs-FlowTM and Facs-
CleanTM) were purchased from Becton, Dickinson, and
Company (Sa˜o Jose, CA). Bio-Rad DC protein assay kit was
purchased from Bio-Rad laboratories (Hercules, CA).
Dulbecco’s modified eagle’s medium (DMEM) with
4,500 mg/L glucose and GlutaMAXTM, fetal bovine serum
(FBS), trypsin (0.25 %)–EDTA (1 mM), and antibiotic
(10,000 U/ml penicillin, 10,000 g/ml streptomycin) were
obtained from Gibco Laboratories (Lenexa, KS).
H9c2 Cell Culture
The H9c2 cell line was a generous gift from Dr. Vilma
Sarda˜o, Center for Neurosciences and Cellular Biology,
University of Coimbra, Portugal. Cells were cultured in
DMEM supplemented with 10 % FBS, 100 U/ml of peni-
cillin, and 100 U/ml of streptomycin in 75 cm2 tissue
culture flasks at 37 C in a humidified 5 % CO2-95 % air
atmosphere. Cells were fed every 2–3 days, and sub-cul-
tured once they reached 70–80 % confluence. After seed-
ing, cells were allowed to grow for 2 days, and then, the
medium was replaced to start the treatments.
Cytotoxicity Assays
Cells were seeded at a density of 35,000 cells/ml in 48-well
plates (final volume of 250 ll; about 8,000 cells/cm2), as
previously described [14]. Concentration–response and
time–response curves of MTX were performed using
incubation times of 24, 48, 72, and 96 h with MTX con-
centration range of 10 nM to 100 lM (10, 100 nM, 1, 5,
10, 50, and 100 lM). Cellular damage was quantitatively
assessed through the measurement of LDH release [19] and
also through the MTT reduction assay [14], as previously
described. For the following experiments, MTX working
concentrations selected were 100 nM and 1 lM based on
cytotoxicity test results.
Studies were also performed by co-incubating for 96 h
MTX with potential protective agents, the reactive spe-
cies scavenger and GSH precursor NAC (1 mM) [20],
and the energetic function enhancer L-carnitine (1 mM)
[21].
Caspase-3 Activity Assay
Caspase-3 activity was determined in H9c2 cells after
100 nM or 1 lM MTX incubation. The incubation period
was defined after pilot studies at 6, 24, and 96 h incubation
period and chosen to be 24 h. The CYP450 inhibitor
metyrapone (0.5 mM) and the CYP2E1 inhibitor diallyl
sulfide (150 lM) were used as possible counteracting agents
to the activation of caspase-3 caused by MTX [14]. Cells
were seeded at a density of 35,000 cells/ml in 6-well plates
(final volume of 2.5 ml, about 9,000 cells/cm2) and allowed
to grow for 2 days. The medium was replaced and cells were
incubated with MTX (100 nM or 1 lM), in the presence or
absence of each metabolism inhibitor, 2 wells per condition.
After 24 h incubation, cells were detached and collected to
tubes (2 wells for one tube). Cells were centrifuged at
2109g for 5 min, at 4 C, and the supernatant was dis-
carded. One hundred and fifty microliters of lysis buffer
(50 mM HEPES, 0.1 mM EDTA, 0.1 % CHAPS, 1 mM
DTT) was added to the pellets. After complete lysis, samples
were centrifuged at 16,0009g, for 10 min, at 4 C. The
supernatant, which contains the cytoplasmatic fraction, was
collected to another tube. All steps were performed on ice.
Caspase-3 activity was determined at 405 nm in a multi-well
plate reader (BioTech Instruments, Vermont, US) as previ-
ously described [19].
The protein content in the cell lysate was quantified using
the Bio-Rad DC protein assay kit as described by the
manufacturer, and albumin solutions were used as standards.
Evaluation of Oxidative Stress
Evaluation of Reactive Species Generation
Cells were seeded at a density of 35,000 cells/ml in 48-well
plates (final volume of 250 ll, about 8,000 cells/cm2) and
allowed to grow for 2 days.
In order to assess the early reactive species generation,
the medium was replaced and cells were incubated with
two different probes, DHR (final concentration 100 lM)
[19] or DCFH-DA (final concentration 10 lM) as previ-
ously described [22], for 30 min at 37 C and in the dark.
After washing cells twice with phosphate-buffered saline in
order to remove non-internalized probes, the new medium
was placed and cells were incubated with MTX (100 nM
and 1 lM). H2O2 (150 lM) was used as a positive control
for the probes [22]. Cells were kept in the dark at 37 C.
The detection and quantification of intracellular reactive
species was performed using a fluorescence plate reader
(baseline 485 nm excitation, 528 nm emission), every
hour, until 10 h incubation.
In order to evaluate the late generation of reactive spe-
cies, cells were first incubated with MTX (100 nM and
1 lM). After 96 h incubation at 37 C, the medium was
replaced and cells were incubated with DCFH-DA
(10 lM), for 30 min, at 37 C, in the dark. At the end of
incubation period, the medium was replaced and the
detection was performed as described above.
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Measurement of Intracellular Total Glutathione (GSHt),
GSH, and GSSG Levels
Cells were seeded at a density of 35,000 cells/ml in 55 cm2
Petri dishes (final volume of 12.5 ml, about 8,000
cell/cm2). After growing for 2 days, the medium was
replaced and MTX (100 nM and 1 lM) was added. After a
24, 48, and 96 h incubation period, the intracellular levels
of GSHt and GSSG in the H9c2 cells were evaluated by the
DTNB-GSSG reductase recycling assay, as previously
described [20].
The protein content was assayed by the Lowry method,
using albumin solutions as standards, as previously descri-
bed [20]. GSHt, GSH, and GSSG contents were normalized
to total protein content, and the final results were expressed
as nmol of GSH or GSSG per mg of protein.
Evaluation of Lipid Peroxidation
Cells were seeded at a density of 35,000 cells/ml in 6-well
plates (final volume of 2.5 ml, about 9,000 cells/cm2).
After growing for 2 days, the medium was replaced for
fresh medium and MTX (100 nM and 1 lM) was added.
Each condition (control, MTX 100 nM, or MTX 1 lM)
was performed in duplicate. After 24, 48, or 96 h incuba-
tion at 37 C, the medium was removed and cells of two
wells were collected with phosphate-buffered saline,
pH = 7.4, on ice to the same centrifuge tube. Cells were
centrifuged (2109g, 5 min, 4 C) and the supernatant was
removed. The obtained pellet of cells was lysed with
100 ll of 5 % HClO4, homogenized, and centrifuged
(16,0009g, 10 min, 4 C). Lipid peroxidation was assessed
by measuring malondialdehyde in the supernatant fraction
through a HPLC/UV method previously described [23],
with some adaptations. The pellet was dissolved in 100 ll
NaOH 0.3 M, and the protein levels were determined by
Lowry method, using albumin solutions as standards.
The HPLC analysis was carried out on a system con-
sisting of a Gilson equipped with UV–VIS detection
(k = 532 nm). Chromatographic separation was achieved
using a Waters C18 Spherisorb 5 lM ODS2 4.6 9 250 mm
column. The mobile phase consisted in 50 mM ammonium
acetate (pH = 5.5): methanol (1:1) ? 0.1 % triethylamine.
The flow rate was maintained isocratically at 0.6 ml/min,
and the total run time was 8 min.
Evaluation of the Energetic Function
Measurement of Intracellular ATP Levels
Cells were seeded and allowed to grow following the same
protocol used for the measurement of glutathione levels.
Conversely, the cells were scrapped and treated with the
same protocol described for the evaluation of glutathione
levels (detailed above). ATP intracellular levels were
measured as previously described [24].
Evaluation of the ATP-synthase Expression
For the in vitro assessment of the ATP-synthase expression,
cells were seeded at a density of 35,000 cells/ml in Petri
dishes (final volume of 12.5 ml, about 8,000 cell/cm2).
After growing for 2 days, the medium was replaced and
MTX (100 nM and 1 lM) was added. After the incubation
periods of 24, 48, and 96 h at 37 C, cells were collected
with phosphate-buffered saline, pH = 7.4, and centrifuged
(2109g, 5 min, 4 C). The supernatant was discarded and
the pellet was lysed with RIPA buffer [50 mMTris-HCl,
150 Mm NaCl, 1 % Igepal CA 630 (v/v), 0.5 % sodium
deoxycholate (w/v), and 0.1 % SDS (w/v), pH = 7.4]
supplemented with protease inhibitors cocktail. The ATP-
synthase expression was evaluated through western immu-
noblot. Equal amounts of protein (quantified using the Bio-
Rad DC protein assay kit) were loaded and electrophoresed
on 10 % SDS–polyacrylamide gel and transferred to poly-
vinylidenedifluoride membrane. Membranes were blocked
with 5 % non-fat milk and incubated with the ATP-synthase
antibody (1:500), overnight at 4 C. Actin (1:500) was used
as loading control. The bands obtained through western blot
were quantified with QuantityOne software (Bio-Rad).
Evaluation of the ATP-synthase Activity
The activity of ATP-synthase was indirectly determined by
analysis of the inorganic phosphate (Pi) released from ATP
hydrolysis. Cells were seeded at a density of 35,000 cells/
ml in Petri dishes (final volume of 12.5 ml, about
8,000 cell/cm2). Cells were allowed to grow for 2 days, the
medium was replaced, and MTX (100 nM and 1 lM) was
added. Cells were incubated for 96 h at 37 C.
After the incubation period, cells were scrapped and
treated with the same protocol described for the evaluation
of ATP-synthase expression (detailed above). The ATP-
synthase activity was determined in the cell lysate using
0.75 mg protein (quantified using the Bio-Rad DC protein
assay kit). The cell lysates were incubated with 2 ml
reaction medium (125 mM sucrose, 65 mM KCl, 2.5 mM
MgCl2, 50 mM HEPES, pH 7.4), at 37 C. Each condition
(control, MTX 100 nM or MTX 1 lM) was performed in
two independent tubes, one of them in the presence of 2 ll
of 1 mg/ml oligomycin (inhibitor of mitochondrial ATP-
synthase). The reaction was started with the addition of
50 ll of 100 mM ATP and was stopped with the addition
of 1 ml 40 % trichloroacetic acid. Then, 1 ml of the
product of this reaction was incubated with 2 ml of freshly
prepared ammonium molybdate reagent containing ferrous
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sulfate and 2 ml distillated water, for 5 min. ATP-synthase
activity is quantified subtracting the difference between the
Pi released by ATP hydrolysis in the presence and
absence of oligomycin. A standard curve of Pi was per-
formed using KH2PO4. The absorbance of the reaction was
measured at 665 nm, and the results were expressed as
nmol Pi/mg/min.
Flow Cytometry Analysis
Intracellular calcium and the evaluation of the mitochon-
drial membrane potential were determined through flow
cytometry using the Fluo-3 AM and TMRM fluorescent
probes, respectively. Cells were seeded at a density of
35,000 cells/ml in 6-well plates (final volume of 2.5 ml,
about 9,000 cells/cm2). After growing for 2 days, the
medium was replaced and MTX (100 nM and 1 lM) was
added (3 wells per condition).
Fluorescence measurements of the cell suspensions were
taken with a flow cytometer (FACSCalibur, Becton Dick-
inson Biosciences) equipped with a 488-nm argon ions
laser. The green fluorescence of Fluo-3 AM was measured
through a 530-nm band-pass filter (FL1), and the red
fluorescence of TMRM was measured through a 575-nm
band-pass filter (FL2). Acquisition data for 15,000 cells
were gated to include only viable cells based on their
forward and side light scatters and the propidium iodide
(5 lg/ml) incorporation. Logarithmic fluorescence was
recorded and analyzed by the BDIS CellQuest Pro software
(Becton Dickinson Biosciences). Non-labeled cells (with or
without MTX) were analyzed in FL1 and FL2 in order to
detect a possible contribution from cells autofluorescence
to the analyzed fluorescence signals. Results were pre-
sented as mean fluorescence intensity (FI).
Assessment of the Mitochondrial Membrane Potential
After 24, 48, and 96 h incubation, the medium was
removed and cells were washed with phosphate-buffered
saline, pH 7.4, and tripsinized with 0.25 % trypsin/1 mM
EDTA in order to obtain a cell suspension. Cells were
centrifuged (2509g, 5 min), the supernatant was discarded,
and cells were suspended in 50 ll culture medium con-
taining 20 nM TMRM [25]. Cells were incubated for
30 min, at 37 C, in the dark. After that, cells were washed
twice with phosphate-buffered saline, pH 7.4, centrifuged
(2109g, 5 min), and kept on ice until flow cytometry
analysis.
Assessment of the Intracellular Calcium Levels
The collection and preparation of the cells was done as in
the assessment of the mitochondrial membrane potential
(see above). The assessment of the intracellular calcium
levels was performed as previously described [26].
Statistical Analysis
Results are presented as means ± the standard deviation
(SD) from independent experiments. Statistical compari-
sons between groups were performed with one-way
ANOVA (in case of normal distribution) or Kruskal–Wallis
test (one-way ANOVA on ranks—in case distribution is
not normal). Significance was accepted at p values \0.05.
Details of statistical analysis are found in the legend of the
figures.
Results
Low Concentrations of MTX Elicit Cytotoxic Effects
in a Time- and Concentration-Dependent Manner
The cytotoxicity of MTX was demonstrated at different
concentrations and time points, through the decline in the
cell viability observed in the LDH leakage assay (Fig. 1)
and through the decrease in the MTT reduction activity
(Fig. 2). The cytotoxic effects observed in these two assays
were dependent on MTX concentration and time of incu-
bation, as shown in the Figs. 1 and 2 (time–response and
concentration–response curves).
The decrease in the cell viability in observed the LDH
leakage assay is related to cell rupture, and results are
shown in the Fig. 1. After 24 h incubation, the lower
concentrations tested (10 nM, 100 nM, and 1 lM) did not
cause significant decreases in the cell viability compared to
control. However, the 24 h incubation with 5 and 10 lM
MTX caused a significant decrease in cellular integrity,
which was more notorious for the highest concentrations
tested, namely 50 and 100 lM MTX. After 48 h, only the
incubation with 10 nM MTX did not decrease cell viability
compared to control cells. The 48 h incubation with
100 nM, 1, 5, 10, 50, and 100 lM caused significant
decreases in cell viability. After 72 h incubation, the
cytotoxicity observed with the 10, 100 nM, and 1 lM
MTX remained similar to the control values. The 72 h
incubation with the other concentrations (5, 10, 50, and
100 lM) caused significant decreases in the cell viability.
The cytotoxicity of MTX was even more evident in the
longest incubation period (96 h). Ten nM MTX did not
change cell viability compared to control; however, slight
decreases were observed with the incubation with 100 nM
and 1 lM MTX, and dramatic effects were observed with
the higher concentrations of 5, 10, and 50 lM.
The reduction of MTT leads to the formation of for-
mazan crystals, mostly by the action of mitochondrial
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Fig. 1 Effect of different
concentrations of MTX on the
H9c2 viability after 24 h (a),
48 h (b), 72 h (c), and 96 h
(d) of incubation at 37 C
evaluated by the LDH leakage
assay. Results are presented as
means (%) ± SD (n = 24 per
condition out of 4 independent
experiments) (***p \ 0.001 vs.
Control). Statistical
comparisons were made using
one-way ANOVA test followed
by the Bonferroni post hoc test
Fig. 2 Effect of different
concentrations of MTX after
24 h (a), 48 h (b), 72 h (c), and
96 h (d) incubation at 37 C
with H9c2 cells evaluated by the
MTT reduction activity assay.
Results are presented as means
(%) ± SD (n = 18 per
condition out of 3 independent
experiments). Statistical
comparisons were made using
one-way ANOVA test
(***p \ 0.001 vs. Control)
followed by the Bonferroni post
hoc test
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dehydrogenases, thereby can be used as a mitochondrial
viability index. After 24 h, the %MTT reduction observed
in the 10 nM MTX incubation was similar to control
values. The incubation with 100 nM or 1 lM MTX
caused slight, but significant, decreases in the %MTT
reduction. More pronounced cytotoxic effects were
observed with the 24 h MTX incubation at 5, 10, 50, and
100 lM concentrations. After 48 h incubation, the %MTT
reduction values in the 10 nM MTX concentration
remained similar to that in the control cells. MTX
100 nM and 1 lM caused slight significant decreases.
Again, more notorious cytotoxic effects were observed
with the higher concentrations of 5, 10, 50, and 100 lM.
After 72 h incubation, the %MTT reduction values
observed with 10 nM were similar to the control values.
The 72 h incubations with higher concentrations (100 nM,
1, 5, 10, 50, and 100 lM) caused significant decreases in
%MTT reduction. Similar to what was observed in the
LDH leakage assay, the cytotoxicity observed by MTT
assay was time dependent being the cytotoxicity higher
with the longest incubation period (96 h). The incubation
with 10 nM MTX did not cause any significant changes in
the %MTT reduction compared to control. The co-incu-
bation with the radical scavenger NAC (1 mM) or the
mitochondrial function enhancer L-carnitine (1 mM) did
not prevent the cytotoxic effects observed with the incu-
bation of MTX (100 nM and 1 lM) for 96 h in the
reduction of MTT test (data not shown).
MTX Incubation Elicits an Increase in the Caspase-3
Activity After 24 h
As can be observed in the Fig. 3, the incubation of 100 nM
and 1 lM MTX, for 24 h, at 37 C, caused an increase in
caspase-3 activity (0.033 ± 0.007 OD/mg protein and
0.039 ± 0.010 OD/mg protein, respectively), compared to
control cells (0.025 ± 0.003 OD/mg protein). The co-
incubation of MTX (in the same concentrations) with the
CYP450 inhibitor metyrapone (0.5 mM) or with the
CYP2E1 inhibitor diallyl sulfide (150 lM) did not prevent
the observed effects in the caspase-3 assay (data not
shown).
Reactive Species Generation and GSH Depletion
after 96 h: No GSSG Formation or Lipid Peroxidation
The effect of MTX in the generation of reactive species
was assessed using two different fluorescent probes,
DCFH-DA (10 lM) and DHR (100 lM). In all the early
time points tested (1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 h), no
changes in intracellular reactive species generation with
any of MTX-tested concentrations (100 nM and 1 lM)
were observed (data not shown). However, as evidenced in
the Fig. 4a), incubations with DCFH-DA after 96 h pre-
incubation with MTX in both working concentrations
caused a significant increase in the generation of reactive
species (137 ± 46.7 % in the MTX 100 nM group and
141 ± 56.9 % in the MTX 1 lM group compared to
100 ± 10.3 % in the control group).
No changes in the GSHt, GSH, and GSSG intracellular
levels after the 24 and 48 h incubations with MTX
(100 nM and 1 lM) were observed (data not shown). Only
when cells were incubated with MTX (100 nM) for 96 h, a
significant decrease was observed in GSHt and GSH
intracellular levels when compared with control group, as
shown in Fig. 4b and c, respectively. No differences were
found in GSSG levels in the previous conditions (data not
shown). No significant changes were observed with the
concentration of MTX 1 lM for GSH, GSHt, or GSSG
intracellular levels (data not shown).
No significant changes were observed in the malondi-
aldehyde levels after incubation with MTX (100 nM and
1 lM) at any time point tested (24, 48, or 96 h) in com-
parison with control levels (data not shown).
MTX-Induced Energetic Impairment and Increased
Levels of Intracellular Calcium at All Time Points
ATP intracellular levels after MTX incubation were assessed
through the bioluminescence test. Significant decreases in
the ATP levels were observed in all time point tested, as
shown in the Fig. 5: after 24 h incubation with MTX
(100 nM and 1 lM), the ATP intracellular levels were about
0.63 ± 0.48 nmol/mg protein and 0.87 ± 0.50 nmol/mg
protein, respectively, compared to 1.77 ± 0.49 nmol/mg
protein for the control group. At the end of 48 h incubation,
ATP levels were 1.23 ± 0.37 nmol/mg protein in the MTX
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Fig. 3 Levels of caspase-3 activity in the H9c2 cells after 24 h
incubation with MTX (100 nM and 1 lM). Results are presented as
mean ± SD (n = 6 independent experiments). Statistical compari-
sons were made using Kruskal–Wallis test followed by the Student–
Newman–Keuls post hoc test (*p \ 0.05 vs. Control)
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100 nM group and 1.18 ± 1.21 nmol/mg protein in the
MTX 1 lM group versus 2.50 ± 0.25 nmol/mg protein for
the control group. After 96 h incubation with MTX (100 nM
and 1 lM), the ATP intracellular levels were about
1.31 ± 0.42 nmol/mg protein and 1.33 ± 0.78 nmol/mg
protein, respectively, compared to 2.20 ± 0.83 nmol/mg
protein for the control group.
The expression of ATP-synthase was evaluated through
western immunoblotting in all time points (24, 48, and
96 h), after incubation with MTX in both working con-
centrations. Results were normalized to the actin content
and were expressed as the optic density ratio between ATP-
synthase/actin (% relative to the control). No significant
changes were observed after 24 or 48 h incubation (data
not shown). In contrast, after the 96 h incubation, signifi-
cant decrease in the ATP-synthase expression was
observed in both treated groups, as evidenced in Fig. 6a, b.
The expression of ATP-synthase was about 86 ± 3.1 % in
the MTX 100 nM group, 84 ± 3.6 % in the MTX 1 lM
versus 100 ± 0.6 % in the control cells. Considering these
differences, the ATP-synthase activity was also evaluated
in MTX-treated cells after 96 h incubation. As shown in
Fig. 6c, after 96 h incubation with MTX (100 nM and
1 lM), the ATP-synthase activity was dramatically
decreased (6.8 ± 3.8 nmol Pi/mg/min and 5.1 ± 1.5 nmol
Pi/mg/min, respectively) compared to control cells
(18.2 ± 4.4 nmol Pi/mg/min).
After incubation with MTX for 24, 48, and 96 h, the
mitochondrial membrane potential and the calcium intra-
cellular levels were evaluated using the TMRM and the
Fluo-3 AM fluorescent probes, respectively. As shown in
the Fig. 7a, after 24 h incubation period, there was an
accumulation of the TMRM probe only with the lower
concentration tested (100 nM) (60 ± 11.9 mean FI),
compared to control (48 ± 10.6 mean FI). The incubation
with MTX 1 lM did not cause significant changes
(43 ± 13.3 mean FI) compared to control values. At the
same time point, the change in the mitochondrial
Fig. 4 Markers of oxidative stress after MTX incubation with H9c2
cells. a Intracellular levels of reactive species detected after
incubation with DCFH-DA (10 lM) fluorescent probe after 96 h
pre-incubation with MTX (100 nM and 1 lM). Results are presented
as means (%) ± SD (n = 6 independent experiments). Intracellular
levels of b GSHt and c GSH after 96 h incubation with MTX
(100 nM and 1 lM). Results are presented as mean ± SD (n = 7
independent experiments). Statistical comparisons were made using
Kruskal–Wallis test followed by the Student–Newman–Keuls post
hoc test (*p \ 0.05 vs. Control)
Fig. 5 ATP intracellular levels after MTX (100 nM and 1 lM)
incubation for a 24 h, b 48 h, and c 96 h. Results are presented as
mean ± SD (n = 5 independent experiments). Statistical
comparisons were made using Kruskal–Wallis test followed by the
Student–Newman–Keuls post hoc test (*p \ 0.05 vs. Control)
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membrane potential was accompanied by a significant
increase in the intracellular calcium levels only in the MTX
100 nM group (88 ± 25.3 mean FI), compared to MTX
1 lM (77 ± 19.3 mean FI) and control group (63 ± 22.6
mean FI) (Fig. 7b). However, after 48 h, both concentra-
tions tested caused a dramatic hyperpolarization of the
mitochondrial membrane potential (79 ± 10.0 mean FI for
MTX 100 nM group and 59 ± 5.2 mean FI for MTX 1 lM
group, compared to 43 ± 7.1 mean FI for control cells)
(Fig. 7a) and increases in the intracellular calcium levels
(56 ± 9.7 mean FI for MTX 100 nM group, 62 ± 7.7
mean FI for MTX 1 lM vs. 40 ± 3.6 mean FI for control
cells) (Fig. 7b). At the last time tested (96 h), the mito-
chondrial membrane potential did not recover to control
(A) CTR               MTX 100 nM      MTX 1 µM
ATP-synthase
Actin
(B) (C)
Fig. 6 a Representative
western blot gel of ATP-
synthase expression in the H9c2
cells after 96 h incubation with
MTX (100 nM and 1 lM).
Actin was used as a loading
control. On b, a graphic
representation of the ATP-
synthase expression is
presented. Results are
normalized to the actin content
and are presented as
mean ± SD (n = 3 independent
experiments). c ATP-synthase
activity in the H9c2 cells after
96 h incubation with MTX
(100 nM and 1 lM). Statistical
comparisons were made using
Kruskal–Wallis test followed by
the Student–Newman–Keuls
post hoc test (*p \ 0.05 vs.
Control)
Fig. 7 a Mitochondrial membrane potential values and b intracellular
calcium levels in the H9c2 cells after incubation with MTX (100 nM
and 1 lM) for 24, 48, and 96 h. Results are presented as mean ± SD
(n = 3 independent experiments). Statistical comparison were made
using Kruskal–Wallis test followed by the Student–Newman–Keuls
post hoc test (*p \ 0.05 vs. Control, **p \ 0.01 vs. Control,
***p \ 0.001 vs. Control)
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values, keeping the same trend observed earlier (75 ± 15.8
mean FI for MTX 100 nM group, 51 ± 7.0 mean FI for
MTX 1 lM group vs. 36 ± 7.6 mean FI for control cells).
Conversely, the calcium intracellular levels of treated cells
remained higher than control cells (134 ± 16.4 mean FI for
MTX 100 nM group, 111 ± 41.8 mean FI for MTX 1 lM
group vs. 66 ± 8.8 mean FI for control cells) (Fig. 7b).
Discussion
In the present work, we showed a time- and concentration-
dependent response to MTX incubation in H9c2 cells,
through two different cytotoxicity tests (LDH leakage
assay and MTT reduction test, Figs. 1 and 2, respectively).
We also contributed to the elucidation of the mechanisms
involved in MTX cellular injury. Our results suggest an
important energetic crisis caused by MTX evidenced by
substantial and early decreases in the ATP intracellular
levels, late inhibition of the ATP-synthase expression and
activity, hyperpolarization of the mitochondrial membrane
potential, and increase in the intracellular calcium levels.
Another 24 h event elicited by MTX was the increase in
the caspase-3 activity, while in our model, oxidative stress
markers were only changed at the longest incubation time
tested.
As already stated, by using several MTX concentrations,
we observed a time- and concentration-dependent cyto-
toxicity pattern in both cytotoxicity tests used, being the
toxic effects observed earlier in the MTT reduction assay
than in the LDH leakage assay in all times tested (Figs. 1,
2). These results suggest that mitochondrial effects antici-
pate cellular membrane rupture in the MTX toxicity.
For studying the mechanisms of MTX cardiotoxicity, we
have selected 2 working concentrations: 100 nM and 1 lM.
Indeed, both MTX concentrations are clinically relevant
given the plasma and tissue levels of MTX found in the
literature [6, 27]. In fact, the mean maximum plasma con-
centrations in humans after a 15 mg/m2 or a 90 mg/m2
30-min infusion of MTX are about 1.5 and 12 lM,
respectively [27]. For the caspase-3 activity assay, the
incubation period of 24 h was selected due to the measur-
able decreases in the cytotoxicity observed in the reduction
of MTT test at this time point in both working concentra-
tions (indicating mitochondrial damage) (Fig. 2) and the
absence of significant decreases in the LDH leakage in the
same conditions (indicative of necrosis). In fact, after 24 h
incubation, despite the absence of significant loss of via-
bility seen on the LDH leakage assay, both chosen MTX
concentrations caused activation of caspase-3 (Fig. 3),
which was in accordance with the described bimodal
mechanism of cell death induced by MTX: apoptosis at
lower concentrations and necrosis at higher concentrations
[28]. Similar signals of apoptosis were already described
after 24 and 48 h of MTX (1.60 lM) incubation in the H9c2
cells [29]. Noteworthy, the late effects of MTX in the
human heart are more related with loss of functionality of
the cells rather than necrosis and lysis.
We recently demonstrated a partial protection toward
MTX cytotoxicity (100 nM and 1 lM) in the same cellular
model after 96 h, with the co-incubation with the CYP450
inhibitor metyrapone (0.5 mM) or with the CYP2E1
inhibitor diallyl sulfide (150 lM) [14]. However, in the
present study, the co-incubation with these metabolism
inhibitors did not prevent the increase in the caspase-3
activity. Altogether, these results suggest that the previous
partial protection obtained with the metabolism inhibitors
is not related to this caspase-dependent activation. In fact,
that protective effect occurred at a late incubation time,
and as we can observe in the present work, the features of
MTX cytotoxicity are rather dissimilar in the time course.
Oxidative stress is described as a possible cellular
mechanism involved in MTX cardiotoxicity, as an attempt
to reveal similarities to the cardiotoxicity caused by
doxorubicin [13]. In fact, MTX contains a quinone group
within its chemical structure that can potentially suffer
oxidative activation leading to reactive species generation
[12, 13]. Both probes employed in the present study are
non-fluorescent that undergo intracellular oxidation to their
respective fluorescent products in the presence of reactive
species such as peroxynitrite, hydroxyl radical, and
superoxide. However, herein, we did not find any strong
evidence of reactive species involvement in earlier MTX
cytotoxicity for 100 nM and 1 lM concentrations. In fact,
until 10 h of incubation, no free radical (peroxynitrite,
hydroxyl radical, or superoxide) generation was observed
by using two different probes, DHR and DCFH-DA. In
accordance, only a very low superoxide anion generation
was described in MCF-7 S9 fractions after incubation with
MTX 100 lM for 30 min, with no hydroxyl radical or
semiquinone formation even for 400 lM MTX [30]. These
results can eventually explain the absence of any lipid
peroxidation or changes in GSHt, GSH, and GSSG intra-
cellular levels observed by us, at 24 and 48 h MTX incu-
bation. After 96 h MTX incubation, a slight decrease in
intracellular GSH for 100 nM MTX (Fig. 4c), a reduction
in GSHt levels (Fig. 4b), and no significant changes in
GSSG and lipid peroxidation were observed. Noteworthy,
we also found a reactive species generation for 100 nM and
1 lM MTX at this late time point (Fig. 4a), which is in
accordance with the previous observation that peroxides
production occurs only after a prolonged incubation with
MTX (1.60 lM) in the H9c2 cells [29]. However, no
changes in intracellular GSH content were observed for
1 lM of MTX: this probably results in some adaptive and
early phenomenon. In fact, oxidative alterations seem to
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occur quite late. One possible explanation is that MTX has
a reduced ability to enter in redox cycle and, consequently,
to produce reactive species in a enzymatic catalyzed
fashion as its congener doxorubicin, while the preferential
metabolic pathway of MTX is two-electron reduction
rather than one-electron reduction [13, 30]. Nevertheless,
we tested NAC in our experimental conditions. Consis-
tently, the co-incubation with the radical scavenger NAC
(1 mM) did not prevent any of the cytotoxic effects
observed with the MTX (100 nM and 1 lM) incubation for
96 h in the MTT reduction test. However, in vivo and
in vitro protective studies using NAC have demonstrated
the efficacy of NAC in reversing the drug-induced car-
diomyopathy related to oxidative stress [20, 31, 32]. The
use of NAC is based on its antioxidant properties and
actions upon the GSH pathways; thus, the lack of protec-
tive effects of NAC in the present study may result in the
fact that other mechanisms involved in MTX toxicity exert
a major role when compared to oxidative stress. Con-
versely, the observed absence of lipid peroxidation is in
accordance with the results obtained in heart homogenates
from MTX-treated mice (15 mg/kg, i.p.) [33]. Noteworthy,
the inhibition of lipid peroxidation was already associated
with MTX in in vitro incubations. In liver microsomes,
heart sarcosomes, and mitochondria isolated from rabbit
incubated with MTX (50, 100, and 200 lM), the levels of
lipid peroxidation were significantly lower than those
observed in controls [34]. These inhibitory effects in lipid
peroxidation still remain unclear, but MTX was described
as having some antioxidant properties [34].
The major finding presented herein is the energetic
imbalance observed in the cells after incubation with MTX
(100 nM and 1 lM). Despite the low MTX concentrations
used, the cellular ATP content decreased around 50 % in
all time tested (24, 48, and 96 h) (Fig. 5). It is known that
H9c2 is a cellular model that privileges the glycolytic
pathway, and MTX seems to interfere with this pathway.
This early ATP crisis could precipitate fatal changes in the
cell. This event can lead to a less efficient calcium control
and mitochondrial electron chain regulation, as we can see
with the increase in intracellular calcium content and the
hyperpolarization of the mitochondrial membrane potential
(Fig. 7). The mitochondrial hyperpolarization should drive
more calcium into the mitochondria matrix and impair
electron chain mitochondrial activity, as we can indirectly
observe in the MTT reduction test and ATP-synthase
activity. The mitochondrial membrane potential may also
be elevated as an attempt to provide motive force to restore
the energetic homeostasis. The increase in the mitochon-
drial membrane potential was also observed in pathological
conditions in ischemic cardiomyocytes during reperfusion
[35], in vascular endothelial cells after pulsatile shear stress
[36], and physiologically during preimplantation stages of
human and mouse embryo development, in response to
metabolic demand [37]. On the other hand and in contrast
to our present work, the incubation of 1.60 lM MTX for
24 h with the H9c2 cells was enough to cause a drop in the
mitochondrial membrane potential [29], while in our lower
concentrations, a hyperpolarization was observed. Con-
sidering the energetic failure, L-carnitine was used by us to
study a possible protection to MTX effects. L-carnitine
(1 mM) is considered a mitochondrial enhancer by
improving the mitochondrial b-oxidation of fatty acids, the
trans-esterification/excretion of acyl-CoA esters, the oxi-
dation of a-ketoacids, and the removal of toxic acylcarni-
tine ester from the mitochondria, providing this metabolic
pathway as a source of ATP synthesis [38, 39, 40].
L-carnitine was already employed in the H9c2 cell model
to study the possible protection against doxorubicin [40].
However, it did not protect the H9c2 cells from the cyto-
toxicity induced by MTX incubation (96 h), evaluated
through the MTT reduction test. Therefore, other mecha-
nisms must be involved in the MTX toxicity towards ATP
pathways.
In our study, a decrease in ATP-synthase expression, but
mostly a drastic reduction in ATP-synthase activity, was
found after 96 h of MTX incubation (Fig. 6). These effects
were not described before for MTX. The decrease in the
ATP-synthase content and activity (Fig. 6) can contribute
to the observed increases in the reactive species generation
at late periods (Fig. 4). This late generation of reactive
species possibly contributes to decrease in GSH. We
evaluated early and late time points of reactive species
formation (until 10 h and after 96 h), but it is easy to
assume that 1 lM MTX caused the formation of reactive
species after those 10 h and before 96 h, allowing an
adaptation feature of GSH synthesis. Noteworthy, GSH is
mainly concentrated in mitochondria and functions as an
internal intracellular antioxidant buffer for the most
important target of oxidative stress in the heart, the mito-
chondria [41].
The energetic dysfunction can result in calcium regu-
lation impairment, since the cellular mechanisms involved
in calcium handling are ATP driven. Thus, at low energetic
levels, calcium pumping activity decreases, resulting in
cytosolic calcium increases [35]. A sustained elevation in
calcium levels can, ultimately, determine the loss of
mitochondrial membrane potential and trigger the cell to
the ‘‘no return point,’’ leading to cell death [42]. Moreover,
the calcium increase may be responsible for the early
activation of caspase-3 observed (Fig. 3). Although the
effects are clear and consistent, it is still difficult to point
out the cause of the initial decrease in ATP level. Note-
worthy, significant decreased levels of ATP were already
demonstrated 72 h after the 3 h pre-incubation of MTX
(about 0.1–10 lM) in cultured neonatal rat cardiac cells
Cardiovasc Toxicol (2013) 13:413–425 423
123
[15], evidencing that even after cessation of that short-
period MTX incubation, the cardiac cells were unable to
recover energetic levels.
Our results suggest that the mild oxidative stress
observed in our study with MTX does not seem to be
related to its redox cycle being secondary to a more dra-
matic and earlier event: the energetic imbalance. The main
results of this study are related to the energetic toxic
effects, evidenced by decreases in the ATP levels, hyper-
polarization of the mitochondrial membrane potential,
increases in the intracellular calcium levels, and late inhi-
bition of the ATP-synthase expression and activity,
observed after MTX incubation with expected therapeutic
concentrations. It is well known that changes in cardiac
energetics can lead to a heart failure condition. Thus, the
results presented here contribute to the elucidation of
mechanisms involved in the cardiotoxicity of MTX.
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